Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading Up 5.4%

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP)’s stock price rose 5.4% on Friday . The stock traded as high as $6.04 and last traded at $5.89. Approximately 1,004,526 shares changed hands during mid-day trading, a decline of 42% from the average daily volume of 1,743,363 shares. The stock had previously closed at $5.59.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Aurinia Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Aurinia Pharmaceuticals Stock Up 12.0 %

The stock has a market cap of $893.08 million, a price-to-earnings ratio of -13.81 and a beta of 1.44. The stock has a 50 day simple moving average of $5.55 and a 200 day simple moving average of $5.61. The company has a quick ratio of 5.05, a current ratio of 5.60 and a debt-to-equity ratio of 0.19.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.01. The firm had revenue of $57.10 million for the quarter, compared to analyst estimates of $54.25 million. Aurinia Pharmaceuticals had a negative net margin of 24.31% and a negative return on equity of 11.75%. The business’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same period last year, the firm earned ($0.08) earnings per share. As a group, analysts expect that Aurinia Pharmaceuticals Inc. will post 0.15 earnings per share for the current fiscal year.

Insider Activity at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, insider Scott Michael Habig sold 18,249 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $5.31, for a total transaction of $96,902.19. Following the completion of the sale, the insider now directly owns 456,338 shares of the company’s stock, valued at approximately $2,423,154.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Campbell & CO Investment Adviser LLC bought a new stake in shares of Aurinia Pharmaceuticals during the 4th quarter worth $2,089,000. GSA Capital Partners LLP raised its position in Aurinia Pharmaceuticals by 196.1% in the first quarter. GSA Capital Partners LLP now owns 349,204 shares of the biotechnology company’s stock worth $1,750,000 after acquiring an additional 231,260 shares during the period. Armistice Capital LLC boosted its stake in Aurinia Pharmaceuticals by 57.7% in the fourth quarter. Armistice Capital LLC now owns 9,536,000 shares of the biotechnology company’s stock valued at $85,729,000 after acquiring an additional 3,488,000 shares during the last quarter. Cetera Advisors LLC grew its position in shares of Aurinia Pharmaceuticals by 18.9% during the 1st quarter. Cetera Advisors LLC now owns 60,139 shares of the biotechnology company’s stock valued at $301,000 after acquiring an additional 9,547 shares during the period. Finally, Capstone Investment Advisors LLC purchased a new stake in shares of Aurinia Pharmaceuticals during the 1st quarter worth approximately $158,000. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.